Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1995-10-20
1998-06-23
Jarvis, William R. A.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
A61K 3144
Patent
active
057706069
ABSTRACT:
Psychogenic impotence or erectile dysfunction can be identified in psychogenic male patients and can be ameliorated, without substantial undesirable side effects, by sublingual administration of apomorphine dosage forms so as to maintain a plasma concentration of apomorphine of no more than about 5.5 nanograms per milliliter.
REFERENCES:
patent: 2818855 (1958-01-01), Miller
patent: 4127118 (1978-11-01), Latorre
patent: 4521421 (1985-06-01), Foreman
patent: 4543256 (1985-09-01), Neumeyer
patent: 4687773 (1987-08-01), Neumeyer et al.
patent: 4727064 (1988-02-01), Pitha
patent: 4801587 (1989-01-01), Voss
patent: 5242391 (1993-09-01), Place et al.
patent: 5270323 (1993-12-01), Milne, Jr. et al.
Tagliamonte et al., Pharm. Biochem. and Behavior 2:257 (1974).
Laudron et al., Biochem. Pharmacology 28:2161-2165 (1979).
Baldessarini et al., in Gessa et al., eds., Apomorphine & Other Dopaminomimetics, vol. 1: Basic Pharmacology, Raven Press, N.Y. (1981), pp. 219-228.
Lal et al., J. Neural. Transmission 54:75-84 (1982).
Gower et al., European J. Pharmacology 122:239-244 (1986).
Segraves et al., Arch. Sexual Behav. 16(2):125-137 (1987).
Melis et al., Brain Research 415:98-104 (1987).
Lal, Prog. Neuro-Psychopharm. & Biol. Psych. 12:117-164 (1988).
Pehek et al., Pharm. Biochem. and Behavior 31:201-208 (1988).
Danjou et al., Br. J. Clin. Pharmac. 26:733-739 (1988).
Gancher et al., Ann. Neurol. 26:232-238 (1989).
Danjou et al., J. Pharmacol. Methods 21:61-69 (1989).
Segraves, Arch. Gen. Psych. 46:275-284 (1989).
Panegyres et al., Med. J. Australia 155:371-374 (1991).
Lal et al., J. Psych. Neurosci. 16(5):262-266 (1991).
Heaton et al., J. Urology 145:1099-1102 (1991).
Montastruc et al., Clin. Neuropharmacology 14(5):432-437 (1991).
Durif et al., Eur. J. Clin. Pharmacology 41:493-494 (1991).
Gancher et al., Movement Disorders 6(3):212-216 (1991).
Essink et al., J. Chromatography 570:419-424 (1991).
Segraves et al., J. Urology 145:1174-1175 (1991).
Durif et al., Clinical Neuropharmacology, 16(2):157-166 (1993).
Seagraves, R.T., Dopamine agonists and their effect on the human penile erectile response, pp. 225-229 in Bancroft, J., editor, The Pharmacology of Sexual Function and Dysfunction, Excerpta Medica, Amsterdam (1995).
Adams Michael A.
El-Rashidy Ragab
Heaton Jeremy P. W.
Morales Alvaro
Jarvis William R. A.
Pentech Pharmaceuticals, Inc.
Queen's University at Kingston
LandOfFree
Dosage forms and method for ameliorating male erectile dysfuncti does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Dosage forms and method for ameliorating male erectile dysfuncti, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dosage forms and method for ameliorating male erectile dysfuncti will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1395039